ExpansionJun 25, 2026, 08:31 AM
Conexeu Sciences Opens New R&D Facility in Vancouver
AI Summary
Conexeu Sciences Inc. announced the opening of its new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. This expansion marks a significant step in advancing the company's regenerative tissue technologies, including its proprietary CXU™ platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix. The new laboratory will serve as the hub for ongoing research, product development, and commercialization efforts, with an anticipated 510(k) submission in early 2027.
Key Highlights
- Conexeu Sciences opened a new R&D facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada.
- The facility is located within the 30,000-square-foot adMare M4 Innovation Centre.
- The new lab will advance the CXU™ regenerative tissue platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix.
- The company anticipates a 510(k) submission in early 2027 for its initial indication.
- Conexeu is targeting multi-billion-dollar end markets including wound care and breast reconstruction.
Price Impact
More from CNXU